Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Arnold Oronsky"'
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
Glioblastoma is an aggressive and inevitably recurrent primary intra-axial brain tumor with a dismal prognosis. The current mainstay of treatment involves maximally safe surgical resection followed by radiotherapy over a 6-week period with concomitan
Externí odkaz:
https://doaj.org/article/313115a120a844ef831e13fd574c20b7
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epige
Externí odkaz:
https://doaj.org/article/7585551884034e63b139be4096e6a690
Autor:
Bryan Oronsky, Sharad Goyal, Michelle M. Kim, Pedro Cabrales, Michelle Lybeck, Scott Caroen, Neil Oronsky, Erica Burbano, Corey Carter, Arnold Oronsky
Publikováno v:
Translational Oncology, Vol 11, Iss 3, Pp 771-778 (2018)
The first tenet of medicine, “primum non nocere” or “first, do no harm”, is not always compatible with oncological interventions e.g., chemotherapy, targeted therapy and radiation, since they commonly result in significant toxicities. One of
Externí odkaz:
https://doaj.org/article/bff3644fac0d46629455af407a14737b
Autor:
Bryan Oronsky, Patrick Ma, Tony R. Reid, Pedro Cabrales, Michelle Lybeck, Arnold Oronsky, Neil Oronsky, Corey A. Carter
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 1, Pp 92-98 (2018)
As the leading cause of cancer-related mortality, lung cancer is a worldwide health issue that is overwhelmingly caused by smoking. However, a substantial minority (~25%) of patients with non–small cell lung cancer (NSCLC) has never smoked. In thes
Externí odkaz:
https://doaj.org/article/e88ef6a30c064cfebb3cfd0bf62dd1f2
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 10, Pp 842-847 (2017)
A few years ago the answer to the question in the title of this review would have been, “unfortunately not much” or even “nothing”, likely eliciting knowing nods of agreement from oncologists. For the last 3 decades, SCLC has been notorious f
Externí odkaz:
https://doaj.org/article/c90338acb376476f948b9e2e9c334510
Autor:
Bryan Oronsky, Scott Caroen, Karen Zeman, Mary Quinn, Christina Brzezniak, Jan Scicinski, Pedro Cabrales, Tony R. Reid, Jane B. Trepel, Nacer D. Abrouk, Christopher Larson, Arnold Oronsky, Harry E. Lybeck, Regina M. Day, Corey A. Carter
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 2016, Iss 10, Pp 105-108 (2016)
Externí odkaz:
https://doaj.org/article/c9f4d2a2985e45c2a112ca31a97a4baf
Autor:
Michelle M. Kim, Hemant Parmar, Yue Cao, Priyanka Pramanik, Matthew Schipper, James Hayman, Larry Junck, Aaron Mammoser, Jason Heth, Corey A. Carter, Arnold Oronsky, Susan J. Knox, Scott Caroen, Bryan Oronsky, Jan Scicinski, Theodore S. Lawrence, Christopher D. Lao
Publikováno v:
Translational Oncology, Vol 9, Iss 2, Pp 108-113 (2016)
BACKGROUND: Kim et al. report two patients with melanoma metastases to the brain that responded to treatment with RRx-001 and whole brain radiotherapy (WBRT) without neurologic or systemic toxicity in the context of a phase I/II clinical trial. RRx-0
Externí odkaz:
https://doaj.org/article/ac84a71275804d769d56c8fbc96deefe
Autor:
Bryan Oronsky, Corey A. Carter, Tony R. Reid, Jan Scicinski, Arnold Oronsky, Michelle Lybeck, Scott Caroen, Meaghan Stirn, Neil Oronsky, Peter Langecker
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 17, Iss 9, Pp 716-722 (2015)
Overall survival (OS) has emerged as the definitive regulatory “be-all, end-all” for the demonstration of benefit in cancer clinical trials. The reason and the rationale for why this is so are easily appreciated: literally a “test of time,” O
Externí odkaz:
https://doaj.org/article/f3fa4b4a8bea4e69a24ca972f3e0b0b0
Autor:
Bryan Oronsky, Jan Scicinski, Michelle M. Kim, Pedro Cabrales, Michael E. Salacz, Corey A. Carter, Neil Oronsky, Harry Lybeck, Michelle Lybeck, Christopher Larson, Tony R. Reid, Arnold Oronsky
Publikováno v:
Biomolecules, Vol 6, Iss 3, p 32 (2016)
First introduced during the late 1800s, radiation therapy is fundamental to the treatment of cancer. In developed countries, approximately 60% of all patients receive radiation therapy (also known as the sixty percenters), which makes radioresistance
Externí odkaz:
https://doaj.org/article/71367208fbdc4d1b968bb51965282064
Publikováno v:
Am J Cancer Res
Transgene-enhanced oncolytic adenoviruses represent a promising novel therapeutic option for the treatment of cancer. A Phase 1 clinical trial featuring AdAPT-001 is ongoing (NCT04673942). AdAPT-001, a type 5 adenovirus, which carries a TGF-β trap t